RSS

Recipharm

Contract development and manufacturing organisation (CDMO) Recipharm has received approval by the European Medicines Verification Organisation (EMVO) to submit serialisation data to the European Hub. more

News

In this interview, we at EPM magazine speak with Staffan Widengren, director of corporate projects at Recipharm on the difficulties CDMOs are facing leading up to the European Falsified Medicines Directive (EU FMD) deadline in February 2019. more

Opinion

Last week, the UK government saw heated debates and closely contested votes on the post-Brexit strategy, including a favourable outcome for the future relationship of the UK and the European Medicines Agency (EMA) more

News

Now we have just passed the six-month marker (1 July) until the European Medicines Agency (EMA) moves from its current location in London to Amsterdam, as a result of Brexit, we gauge industry response to this change… more

Opinion

CDMO, Recipharm, has acquired Sanofi’s manufacturing centre and business located in Holmes Chapel, which will provide the company with a platform to take advantage of the growing respiratory drug market. more

News

Contract development and manufacturing organisation (CDMO), Recipharm, has partnered with Hadasit Medical Research Services and Development to deliver combined clinical, biological and chemical services. more

News

Contract development and manufacturing organisation (CDMO), Recipharm, has been recognised in the CMO Leadership Awards for 2018, organised by Life Science Leader. more

News

Contract development and manufacturing organisation (CDMO), Recipharm, has revealed that the winner of its 2017 International Environmental Award is Karen Kidd more

News

Contract development and manufacturing organisation (CDMO), Recipharm, has signed a licensing agreement with Canadian drug development company, Altus Formulation, to offer new drug delivery technologies for value added medicines. more

Technology

Today (Friday 9 Feburary 2018) marks the precise point that we are a year away until the European Union Falsified Medicines Directive (EU FMD) comes into force. Here, we feature some expert opinions more

Opinion

Recipharm has taken a step further in its development and growth in the Indian market by acquiring the remaining shares in Nitin Lifesciences. more

News

Mark Quick, executive vice president of corporate development, Recipharm, goes into detail about the opportunities his company has faced this year as well as the challenges. more

Opinion

With the industry experiencing dramatic change, from regulatory changes to investments in capacity and the uncertainty of the political landscape, we asked several industry heads to review the opportunities, challenges and trends of 2017. more

Opinion

CDMO, Recipharm, has been awarded with ‘le Prix d’Excellence 2017 — Spécial Sciences de la vie’ by the Swedish Chamber of Commerce in France in recognition of its commitment to its French operations more

News

Today (Monday 27 November) marks the original deadline date for the DSCSA. While the FDA has delayed its enforcement of compliance with these serialisation requirements by a year, pharma is still required to legally comply. Industry tells us more… more

Opinion

Here we count down the top five tweets from @EPM_magazine that have gained the most impressions this week, taken from Twitter analytics. more

News

Traditionally, excipient selection has been performed using trial-and-error based methodologies, which are time-consuming and expensive. In this article, Dr Amjad Alhalaweh, PhD, formulation scientist, Recipharm, discusses a new method, HTS more

Opinion

In this roundtable, four industry leaders from Symbiosis Pharmaceutical Services, Recipharm, Sterling Pharma Solutions and Idifarma, reveal their thoughts on what the ‘mega trends’ are in the current pharma landscape. more

, , , Opinion

Here, we reveal some of the news, developments and product innovations that have been released from the show floor of day 1 of this year’s CPhI Worldwide congress in Frankfurt more

News

Contract development and manufacturing organisation (CDMO) — Recipharm and Kancera, a development company focused on cancer therapy, have entered into a contract for the development and manufacture of the pharmaceutical candidate KAND567. more

News